Drug intelligence / Profile preview

TR115

Development stage: Phase 3
Lead developer: Tarapeutics Science
Modality: Small Molecules
Administration: Oral

Overview

TR115 is an investigational small molecule inhibitor of Enhancer of Zeste Homolog 2 (EZH2), currently in Phase 1 clinical trials for the treatment of relapsed or refractory non-Hodgkin's lymphoma and advanced solid tumors. The drug is administered orally as a tablet and is being developed to assess its safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy. The primary developer is Tarapeutics Science Inc., with involvement from Anhui Zhongke Tuoran Pharmaceutical Research Co., Ltd. Clinical studies are ongoing in China.

Targets

EZH2 (Histone-lysine N-methyltransferase EZH2)

Beyond the preview

Go deeper on TR115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TR115.

Explore the full profile